EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Basculer en Français

10809	Companies
234028	Keywords
162739	Articles
125009	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

PRESS RELEASE

published on 04/16/2024 at 15:00, 2 years 3 months ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRIEF

published on 04/09/2024 at 14:50, 2 years 3 months ago

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRIEF

published on 04/09/2024 at 14:50, 2 years 3 months ago

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
PRESS RELEASE

published on 04/09/2024 at 14:45, 2 years 3 months ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRIEF

published on 03/15/2024 at 14:05, 2 years 4 months ago

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRIEF

published on 03/15/2024 at 14:05, 2 years 4 months ago

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
PRESS RELEASE

published on 03/15/2024 at 14:00, 2 years 4 months ago

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRIEF

published on 03/06/2024 at 14:45, 2 years 4 months ago

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRIEF

published on 03/06/2024 at 14:45, 2 years 4 months ago

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
PRESS RELEASE

published on 03/06/2024 at 14:40, 2 years 4 months ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Accesswire

Published on 08/06/2026 at 13:10, 27 minutes ago

Camino Announces $5.0 Million Brokered Private Placement of Units and Concurrent $9.5 Million Non-Brokered Private Placement of Convertible Debentures
Published on 08/06/2026 at 13:00, 37 minutes ago

Azarga Metals Appoints Matt Bolu to Board of Directors
Published on 08/06/2026 at 13:00, 37 minutes ago

Grid Metals Commissions Mineral Resource Estimate for Falcon West; Announces Final Assays from Phase 2 Drill Program
Published on 08/06/2026 at 13:00, 37 minutes ago

Unusual Machines Second Quarter 2026 Shareholder Letter
Published on 08/06/2026 at 13:00, 37 minutes ago

Electrovaya to Participate in Upcoming Investor Conferences

View all ACCESSWIRE

EQS Group

Published on 08/06/2026 at 13:04, 33 minutes ago

Halfords Group PLC: Holding in Company
Published on 08/06/2026 at 13:00, 37 minutes ago

Fresenius transitions to registered shares – automatic conversion for shareholders
Published on 08/06/2026 at 12:05, 1 hour 31 minutes ago

CULTURAL DISRUPTORS AND CULINARY ICONS UNVEILED AS THE GLOBAL JURY FOR THE S.PELLEGRINO YOUNG CHEF ACADEMY COMPETITION 2026-27
Published on 08/06/2026 at 11:50, 1 hour 46 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 08/06/2026 at 11:30, 2 hours 6 minutes ago

Partners Group to become majority shareholder in data center power solutions provider AVK and accelerate future growth

Les Echos

Published on 08/06/2026 at 08:44, 4 hours 52 minutes ago

IDI annonce la cession du groupe Talis à son fondateur, Serge Marcillaud, accompagné de l'équipe dirigeante
Published on 08/06/2026 at 08:00, 5 hours 37 minutes ago

EURAZEO ENTRE EN DISCUSSIONS EXCLUSIVES AVEC PARTNERS GROUP EN VUE DE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET DE SON RÉINVESTISSEMENT À SES CÔTÉS
Published on 08/06/2026 at 08:00, 5 hours 37 minutes ago

EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/06/2026 at 07:48, 5 hours 48 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 juillet 2026
Published on 08/05/2026 at 18:00, 19 hours 37 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026

View all LES ECHOS COMFI WIRE